Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
ARS Pharmaceuticals (SPRY)
NASDAQ:SPRY
ARS Pharmaceuticals (SPRY) Stock Price & Analysis
224 Followers
SPRY Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.55 - $11.41
Previous Close$11.35
Volume697.57K
Average Volume (3M)561.16K
Market Cap
$1.10B
Enterprise Value$876.35M
Total Cash (Recent Filing)$223.63M
Total Debt (Recent Filing)$217.00K
Price to Earnings (P/E)―
Beta1.26
Next Earnings
Aug 08, 2024EPS Estimate
-$0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.52
Shares Outstanding96,895,256
10 Day Avg. Volume488,987
30 Day Avg. Volume561,157
Standard Deviation0.21
R-Squared0.04
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)3.44
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-11.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue87.63K
Enterprise Value/Gross Profit29.21K
Enterprise Value/Ebitda-20.61
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering1
ARS Pharmaceuticals News
PremiumCompany Announcements
ARS Pharmaceuticals Updates Corporate Presentation Online
PremiumCompany Announcements
ARS Pharmaceuticals: Corporate Update and EURneffy’s Positive Opinion
PremiumCompany Announcements
ARS Pharmaceuticals Unveils Updated Corporate Presentation
Bulls Say, Bears Say
Bulls Say
Commercial StrategyManagement's efforts to proactively prime the allergy market are expected to strengthen the uptake for neffy's anticipated US launch.
Market Expansion'neffy' could address a significant global unmet need, potentially expanding market opportunities.
Regulatory MilestoneThe potential positive EMA opinion for 'neffy' could provide investors with added conviction ahead of the PDUFA date.
Bears Say
Advisory Committee ExpectationsThe CRL was a surprise given the prior positive recommendation from the Pulmonary-Allergy Drug Advisory Committee.
Market Entry DelaysThe FDA issued a Complete Response Letter for neffy, indicating a shift in their approval standards and resulting in a delay for the product's potential market entry.
Regulatory ChallengesARS Pharmaceuticals announced the FDA issued a Complete Response Letter (CRL) for neffy, requesting additional studies and information on nitrosamine impurities.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
SPRY FAQ
What was ARS Pharmaceuticals’s price range in the past 12 months?
ARS Pharmaceuticals lowest stock price was $2.55 and its highest was $11.41 in the past 12 months.
What is ARS Pharmaceuticals’s market cap?
Currently, no data Available
When is ARS Pharmaceuticals’s upcoming earnings report date?
ARS Pharmaceuticals’s upcoming earnings report date is Aug 08, 2024 which is in 17 days.
How were ARS Pharmaceuticals’s earnings last quarter?
ARS Pharmaceuticals released its earnings results on May 09, 2024. The company reported -$0.11 earnings per share for the quarter, missing the consensus estimate of -$0.099 by -$0.011.
Is ARS Pharmaceuticals overvalued?
According to Wall Street analysts ARS Pharmaceuticals’s price is currently Overvalued.
Does ARS Pharmaceuticals pay dividends?
ARS Pharmaceuticals does not currently pay dividends.
What is ARS Pharmaceuticals’s EPS estimate?
ARS Pharmaceuticals’s EPS estimate is -$0.12.
How many shares outstanding does ARS Pharmaceuticals have?
ARS Pharmaceuticals has 96,895,256 shares outstanding.
What happened to ARS Pharmaceuticals’s price movement after its last earnings report?
ARS Pharmaceuticals reported an EPS of -$0.11 in its last earnings report, missing expectations of -$0.099. Following the earnings report the stock price went down -0.682%.
Which hedge fund is a major shareholder of ARS Pharmaceuticals?
Among the largest hedge funds holding ARS Pharmaceuticals’s share is Deerfield Management Company, LP. It holds ARS Pharmaceuticals’s shares valued at 113M.
---
ARS Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
― (―)
― (―)
Blogger Sentiment
Bullish
SPRY Sentiment 83%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 87.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.0%
Last 30 Days ▲ 8.7%
Last 30 Days ▲ 8.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
69.40%
12-Months-Change
Fundamentals
Return on Equity
-20.49%
Trailing 12-Months
Asset Growth
-16.08%
Trailing 12-Months
Company Description
ARS Pharmaceuticals
Silverback Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on leveraging its ImmunoTAC technology platform to develop tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases.
---
SPRY Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Best Analysts Covering SPRY
1 Year
1 Year Success Rate
8/10 ratings generated profit
1 Year Average Return
+79.61%
assigned a buy rating 4 months ago
Copying Andreas Argyrides's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +79.61% per trade.
---